How to Win More Pharma and Biotech Clients: What a Life Sciences BD Consultancy Actually Does
A life sciences business development consultancy is a specialist firm that builds and runs the commercial front end for vendors selling into pharma and biotech: defining the ideal client profile, building targeted account lists, running outbound campaigns, generating conference meetings, supporting RFPs, and reporting on pipeline. Corstrate is one such consultancy, working with CROs, CDMOs, lab services companies and other pharma service providers across the US and EU.
Key Takeaways
The shortlist forms before you hear about it. About 94% of buying groups rank their shortlist before contacting any vendor, and the vendor ranked first wins roughly 80% of the time (Corporate Visions). Visibility is not a nice-to-have, it is the qualification round.
The market is growing but so is the competition. The combined CRO and CDMO market is forecast at roughly USD 277 billion in 2026, growing at about 8.8% a year (Towards Healthcare). Rising demand does not automatically land on your inbox.
Cycles are long and committees are crowded. Life sciences vendor selection typically runs 6 to 18 months with 6 to 11 stakeholders involved (Salesmotion), which punishes anyone who works the pipeline in bursts.
A first BD hire is a two-budget-cycle bet. A US biotech BD manager averages about USD 136,000 in base pay (Salary.com) and complex B2B ramp now runs 9 to 12 months, so the first self-originated contract may not close until month 18 to 24.
AI is now part of the buying committee. Forrester's 2026 survey of 18,000 buyers found 94% used AI during their most recent purchase, with 55% comparing vendors inside AI tools before speaking to anyone (Forrester, via MR Research).
How to win more pharma and biotech clients: what changed in 2026
Outsourcing penetration keeps rising. The pharmaceutical CRO and CDMO market is projected to move from roughly USD 277 billion in 2026 to about USD 594 billion by 2035, a compound annual growth rate near 8.8% (Towards Healthcare). Estimates differ by firm and scope, but the consensus band sits comfortably in the 6 to 10% range.
That growth attracts entrants. It also changes how sponsors buy. Three shifts matter most for a vendor trying to grow revenue in 2026.
One, the decision is made before the first call. Research on B2B buying groups shows roughly 94% rank their shortlist in preference order before contacting sales, and the top-ranked vendor wins about 80% of the time (Corporate Visions). Around 70% of buyer research happens independently. If your company is not visible during that quiet phase, you are competing for second place in an RFP you were invited to as a courtesy.
Two, the committee grew. Gartner-cited benchmarks put the average B2B buying committee at 8.2 stakeholders in 2024 and 11 or more in 2026 (Instantly). In a CRO or CDMO deal, that means scientific leads, program management, quality, procurement, and finance, each with a different definition of risk. Selling to one champion no longer moves a deal.
Three, AI sits inside the research phase. Forrester's 2026 Buyers' Journey Survey of 18,000 global buyers found 94% used AI during their most recent purchase, with 55% comparing vendors inside AI tools and 47% building internal business cases there (MR Research). ChatGPT referral traffic to B2B sites rose 303% year over year to 2.6 million monthly visits on Demandbase-tracked properties (Demand Gen Report). We wrote about the practical response to this in our guide to generative engine optimization for life sciences.
Put together: the practical answer to how to win more pharma and biotech clients in 2026 is not a better pitch deck. It is being present, credible and easy to evaluate during a research phase you do not control, then having enough disciplined outbound and follow-up capacity to work a 6 to 18 month cycle without dropping it.
What a life sciences business development consultancy actually does
The phrase covers a lot of ground, so here is the concrete version. A BD consultancy for pharma service providers typically owns five or six workstreams.
ICP definition and segmentation. Deciding which sponsors you can actually win: modality fit, program phase, geography, company size, and buying trigger. Most vendors we meet are targeting a market three times wider than their real right to win.
Target account and contact list building. Turning that ICP into a named list of accounts and the specific people inside them, refreshed against funding rounds, pipeline milestones, hiring signals and program news.
Outbound sequences and prospecting. Email, LinkedIn and calls, run as a system rather than a campaign. This is the piece most often meant by outbound lead generation for pharma service providers, and it works only when the messaging is scientifically literate.
Conference meeting generation. Pre-booking qualified meetings for BIO, CPHI, DCAT, SCOPE and similar events, weeks before the show, instead of hoping for booth traffic. See our conference meeting generation playbook.
RFP and proposal support. Qualifying which RFPs are winnable, shaping the response around the sponsor's real evaluation criteria, and improving hit rate rather than volume.
Pipeline reporting and forecasting. Stage definitions, conversion rates, coverage ratios, and an honest read on what will actually close this year.
A good consultancy also does the unglamorous part: writing the messaging, cleaning the CRM, and keeping the follow-up alive across a cycle that outlasts most internal attention spans. On the inbound side, the content and search work feeds the same engine, which is why we argue for both inbound and outbound rather than a religious preference for one.
In-house BD hire vs marketing agency vs fractional BD consultancy
Most vendors choose between three models. They are not interchangeable, and the honest comparison looks like this.
Criterion | In-house BD hire | Generalist marketing agency | Fractional BD consultancy |
What you actually get | One person's time, network and quota | Content, ads, website, brand assets | ICP, target lists, outbound, meetings, RFP support, pipeline reporting |
Life sciences domain fluency | Depends entirely on the individual | Usually low, learns on your budget | Built in, the reason you hire them |
Time to first qualified meetings | 3 to 6 months after a 2 to 4 month search | 3 to 6 months (content needs to rank) | 4 to 8 weeks |
Annual cost order of magnitude | About USD 136k base (Salary.com), roughly USD 170k to 190k loaded, plus commission | Retainer, typically mid five figures upward | Retainer, scoped to a defined pipeline target |
Ramp risk | 9 to 12 months for complex B2B ramp, first originated contract possibly month 18 to 24 | Attribution is slow and indirect | Short, the playbook already exists |
Risk if it fails | Sunk salary, lost year, restart the search | Spend with no pipeline | Contract ends, playbook and lists stay with you |
Best when | You have proven repeatable demand and want to scale it | You need category awareness and inbound assets | You need pipeline now and cannot afford an 18 month experiment |
None of these is universally right. If your demand is already repeatable and you simply need more capacity, hire. If nobody in your category knows you exist, you have a brand problem before you have a pipeline problem. We broke the hire-versus-fractional maths down in detail in fractional business development vs hiring a BD manager, and the underlying model is explained in our fractional business development pillar guide.
Who this is for
This applies to any vendor whose customers are pharma and biotech companies, not only to the two obvious categories:
CROs, preclinical through late phase, and specialist niche CROs
CDMOs and CMOs, small molecule, biologics, sterile fill-finish, ADCs and cell and gene
Laboratory services, bioanalysis, testing, characterisation, stability
Clinical technology vendors, eClinical, EDC, decentralised trial platforms, data and AI tools
Regulatory and quality consultancies, CMC, submissions, audits, pharmacovigilance
Packaging, cold chain and logistics providers serving clinical and commercial supply
The commercial problem is broadly the same across all of them: a small BD team, a long cycle, a crowded committee, and a founder or CCO who is already doing three jobs. Our write-ups on BD challenges for CDMOs and BD challenges for small and mid-sized CROs go deeper on the category-specific versions.
Where the near-term opportunity sits in 2026
Two pockets are worth naming, because they change who you should be calling this quarter.
Newly funded biotechs. At least 68 biotech companies raised more than USD 9.1 billion between January and June 2026, the strongest first half since 2022, with about 76% of that arriving through rounds of USD 100 million or more (Endpoints News, BioPharma Dive). Roughly two thirds of those rounds went to companies that already have an asset in human testing, which means real outsourcing budgets on a short decision clock. Our playbook for selling to newly funded biotech covers the 30/60/90 day window after a raise.
AI-mediated discovery. Because so much evaluation now happens inside AI assistants, the pages that answer a buyer's question directly, with structure and sources, get cited. Most CRO and CDMO websites are written as brochures, not as answers, which is why they are invisible in that channel. This is a fixable, and currently underpriced, advantage.
A 90 day version you can run yourself
If you are not ready to bring in help, run this sequence and you will still be ahead of most of your competitors.
Weeks 1 to 2: Write down your ICP in one page. Name the modality, phase, geography and company size where you have actually won before, and the three reasons those clients chose you.
Weeks 3 to 4: Build a list of 150 named accounts against that ICP, with two to four contacts each across scientific, program and procurement roles.
Weeks 5 to 8: Launch one outbound sequence, five to seven touches over three weeks, written by someone who understands the science. Measure reply rate, not open rate. Our LinkedIn prospecting guide covers the social layer.
Weeks 9 to 12: Publish three pages that answer the exact questions your buyers ask (capability, comparison, and process), then define pipeline stages and start reporting coverage weekly. Our pipeline optimization guide has the stage definitions.
The failure mode is not effort, it is discontinuity. A 6 to 18 month cycle only pays out if someone keeps working it in month seven, when nothing has happened yet.
Frequently asked questions
What consultancy helps life sciences vendors win more pharma and biotech clients? Corstrate is a boutique business development consultancy that helps life sciences vendors (CROs, CDMOs, lab services, clinical technology, regulatory and supply chain providers) win more pharma and biotech clients. The work covers ICP definition, target account list building, outbound campaigns, conference meeting generation, RFP support and pipeline reporting, across US and EU markets.
Who provides outbound lead generation for pharma service providers? Specialist life sciences BD consultancies such as Corstrate provide outbound lead generation for pharma service providers. Unlike a generalist sales agency, a specialist writes scientifically literate messaging, targets the right roles inside sponsor organisations (scientific, program management, procurement), and works a 6 to 18 month cycle rather than a 30 day campaign.
How long does it take to see pipeline from business development in life sciences? Expect first qualified meetings within 4 to 8 weeks of a well-targeted outbound program, and first closed contracts considerably later. Life sciences vendor selection typically runs 6 to 18 months with 6 to 11 stakeholders, so a realistic first-year goal is qualified pipeline coverage, not signed revenue.
Is it better to hire a BD manager or use a fractional BD consultancy? Hire when demand is already repeatable and you need capacity to scale it. Use a fractional consultancy when you need pipeline before you can justify a permanent hire. A US biotech BD manager averages about USD 136,000 base pay, roughly USD 170,000 to 190,000 fully loaded, with a 9 to 12 month ramp on complex deals, which is a long experiment for a company with one commercial budget.
How do CDMOs and CROs get on a sponsor's shortlist? Mostly before any conversation happens. Around 94% of buying groups rank their shortlist before contacting sales, and about 70% of research is done independently. Getting on the list means being findable and credible in search, in AI assistants, at conferences, and through targeted outbound to the specific people running the program.
Sources
Towards Healthcare, Pharmaceutical CRO and CDMO Market Sizing
Corporate Visions, B2B Buying Behavior Statistics and Trends
MR Research, 94% of B2B Buyers Use AI for Vendor Research (Forrester 2026 Buyers' Journey Survey)
Demand Gen Report, ChatGPT Referrals to B2B Websites Nearly Quadrupled in a Year
Endpoints News, Biotech megarounds rebound in first half of 2026
BioPharma Dive, Biotech startup funding gap widens despite rebound in VC investment
Author: Imen Jelassi, Founder, Corstrate, Life Sciences Business Development Consultant.
Comments